As Markets Falter, These Stocks Surge: The Surprising Heroes of Wall Street
Regeneron Pharmaceuticals’ stock surged by 4%, driven by promising Dupixent trial results in collaboration with Sanofi, targeting the rare condition bullous pemphigoid. Biogen, trading at an attractive 13.5 times earnings, positions itself for growth through investments in new projects and research in
